Syntekabio will present its innovative AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference on August 19, 2022, in Arlington, VA. Dr. Kilyoung Kim will lead the presentation, emphasizing the company’s dedication to revolutionizing drug development. The conference aims to promote U.S.-Korea collaboration in science and technology for aspiring entrepreneurs and industry leaders.
Syntekabio, a leader in artificial intelligence drug discovery, will unveil its innovative AI-based cloud platforms, DeepMatcher® and NEO-ARS™, at the upcoming US-Korea Conference (UKC) on August 19, 2022, in Arlington, Virginia. These platforms are set to launch in September and showcase Syntekabio’s commitment to revolutionizing drug discovery and development. The event will promote collaboration between American and Korean professionals in the fields of science, engineering, and technology, facilitating networking and business opportunities for entrepreneurs.
Dr. Kilyoung Kim, the Chief Scientific Officer and President of Syntekabio USA, will represent the company at the Innovation and Entrepreneurship Symposium, where he will provide insights into their latest advancements. Participants will engage in discussions to foster cross-border business relations and explore recent developments in the industry. The symposium serves as a valuable platform for Syntekabio and similar companies to showcase innovative technologies and products to influential figures in the market.
The US-Korea Conference, particularly the Innovation and Entrepreneurship Symposium, provides a unique environment for aspiring entrepreneurs to connect with industry veterans and investors. This year’s conference is expected to cover emerging trends, novel technologies, and sustainable business strategies that contribute to the advancement of the biomedical sector. The venue for this significant gathering will be the Hyatt Regency Crystal City in Arlington, Virginia, commencing at 5 p.m. ET on August 19, 2022.
The US-Korea Conference (UKC) is an annual event designed to enhance collaboration across various disciplines between the United States and South Korea. This conference fosters an environment conducive to networking, sharing innovative ideas and technologies, and identifying cross-border opportunities. Syntekabio, founded in 2009 and headquartered in South Korea, specializes in leveraging artificial intelligence and big data for drug discovery and development. Their AI-based platforms, DeepMatcher® and NEO-ARS™, exemplify the application of advanced technology to streamline and innovate drug discovery processes, aiming to improve global healthcare outcomes.
In summary, Syntekabio’s upcoming presentation at the 2022 US-Korea Conference signifies a crucial step towards integrating cutting-edge AI technology in the pharmaceutical industry. The launch of DeepMatcher® and NEO-ARS™ reflects a commitment to enhancing drug discovery efficiency and fostering international collaboration in biotechnology. By participating in this prestigious event, Syntekabio aims to forge valuable connections and showcase their advancements in transformative medicine for worldwide health improvement.
Original Source: www.globenewswire.com
